# Apnimed Files for Up to $160M IPO to Fund Sleep Apnea Drug Launch

> financing · REPORTED · 2026-07-28

On July 27–28, 2026, Apnimed set terms for its IPO offering 10 million shares at $14–$16 each, targeting up to approximately $160 million in gross proceeds to support the potential commercial launch of its lead obstructive sleep apnea oral therapy Oxnimbi (AD109). At the midpoint of the range the company would be valued at over $600 million.

About Apnimed: Apnimed is a clinical-stage biotech developing pharmacological treatments for obstructive sleep apnea, with Oxnimbi (AD109) being a first-in-class oral noradrenergic agent designed to restore upper-airway muscle tone during sleep.

- Company: Apnimed
- Sector: therapeutics
- Primary source: https://www.biospace.com/business/apnimed-eyes-up-to-160m-ipo-to-prep-for-sleep-apnea-drug-launch

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.